Medical weight management | New York
Wegovy injection is semaglutide given under the skin once weekly. Its current U.S. label includes long-term weight reduction for adults with obesity, adults with overweight and a weight-related condition, and patients age 12 years and older with obesity. It also includes cardiovascular risk reduction for certain adults and an accelerated-approval indication for adults with noncirrhotic MASH and F2 to F3 fibrosis. The 2026 label adds a 7.2 mg Wegovy HD dose for certain adults who need additional weight reduction after tolerating 2.4 mg.
Wegovy injection is FDA approved and commercially available in the United States. The combined tablet and injection label was revised in June 2026. Nao Medical provides evaluation and care coordination. A prescription, coverage, dispensing, teaching visit, or administration is never automatic.
The injection has weight, cardiovascular, pediatric, and MASH indications with different eligibility and dosing details. The MASH indication is for adults with noncirrhotic disease and moderate-to-advanced F2 to F3 fibrosis and remains under accelerated approval.
The clinician should identify the exact indication, age, weight and cardiovascular history, liver diagnosis when relevant, and current medicines. The review also covers diabetes and eye history, gastrointestinal or gallbladder concerns, kidney context, pregnancy and procedure plans, contraindications, and device readiness.
The injection starts at 0.25 mg once weekly and uses staged escalation. Adult weight maintenance is usually 1.7 mg or 2.4 mg weekly. The current label allows 7.2 mg weekly for certain adults after at least four weeks at 2.4 mg when additional weight reduction is clinically indicated. Other indications have specific maintenance instructions.
Follow-up should address response, gastrointestinal effects, hydration and kidney concerns, gallbladder or pancreatitis symptoms, blood glucose when relevant, retinopathy history, heart rate, hypersensitivity, and injection technique. MASH care requires liver-specific monitoring and coordination.
A brand name is not enough to determine whether treatment is appropriate. The clinician must connect the label to the patient's diagnoses, current medicines, prior treatment, laboratory results, preferences, and coverage.
The clinician should identify the exact indication, age, weight and cardiovascular history, liver diagnosis when relevant, and current medicines. The review also covers diabetes and eye history, gastrointestinal or gallbladder concerns, kidney context, pregnancy and procedure plans, contraindications, and device readiness.
Follow-up should address response, gastrointestinal effects, hydration and kidney concerns, gallbladder or pancreatitis symptoms, blood glucose when relevant, retinopathy history, heart rate, hypersensitivity, and injection technique. MASH care requires liver-specific monitoring and coordination.
Nao Medical must confirm age boundaries, the Wegovy HD pathway, device teaching, payer access, adverse-effect triage, and liver-specialist coordination before public scheduling begins.
Do not apply one Wegovy indication to every patient or dosage form. Oral Wegovy does not carry the injection's pediatric or MASH indications. Wegovy should not be used with another semaglutide product or another GLP-1 receptor agonist.
An evaluation may lead to another medicine, more testing, a referral, or no medication change.
The health plan and dispensing pharmacy make coverage and fulfillment decisions. Prior authorization may be required.
The clinic cards below show places to start an evaluation. They do not prove that a product is stocked, dispensed, taught, or administered at that site.
The sequence protects safety and keeps a product request from bypassing diagnosis, records, monitoring, access, or referral needs.
The clinician reviews weight history, prior treatment, current medicines, related conditions, pregnancy plans when relevant, and the patient's goals.
The visit addresses label criteria, contraindications, interactions, side effects, nutrition, activity, and whether another treatment path is more appropriate.
If a prescription is appropriate, the team discusses the dosage form, administration instructions, coverage process, and follow-up. Approval and supply are not guaranteed.
Follow-up considers response, tolerability, adherence, dose changes, related conditions, and whether treatment should continue or change.
Choose a nearby Nao Medical clinic as a starting point for evaluation or care coordination.
Capability boundary: these location cards do not establish that a medicine, device, laboratory test, injection, or specialty workflow is available at every site. Confirm the exact service before travel.
Bronx
932 E 174th St, Bronx, NY 10460
A place to begin evaluation and care coordination near West Farms, Crotona Park East, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
37-15 23rd Ave, Astoria, NY 11105
A place to begin evaluation and care coordination near Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Bronx
2063A Bartow Ave, Bronx, NY 10475
A place to begin evaluation and care coordination near Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A place to begin evaluation and care coordination near Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A place to begin evaluation and care coordination near Hicksville, Plainview, Bethpage, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A place to begin evaluation and care coordination near Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A place to begin evaluation and care coordination near Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
30-07 36th Ave, Astoria, NY 11106
A place to begin evaluation and care coordination near Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
135 Mineola Blvd, Mineola, NY 11501
A place to begin evaluation and care coordination near Mineola, Garden City, Westbury, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Manhattan
259 1st Ave, New York, NY 10003
A place to begin evaluation and care coordination near StuyTown, the East Village, Gramercy, and nearby Manhattan neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A place to begin evaluation and care coordination near Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Compare care options, prepare for an evaluation, and connect medication questions with broader care.
Explore Nao Medical's broader weight-management program and treatment options.
Review the adult tablet pathway and its fasting administration rules.
Review Wegovy's liver indication, diagnosis, and specialist-coordination questions.
Compare tirzepatide using its own label and safety information.
Review a different oral GLP-1 product and interaction profile.
Answers reflect the current official sources and the limited evaluation-and-coordination scope described above.
These sources support product identity, approval, current labeling, availability, and clinical boundaries. They do not prove Nao Medical site capability or health-plan coverage.
Current injection and tablet indications, Wegovy HD, dose escalation, contraindications, and safety information.
Open official sourceMarch 2026 Wegovy HD approval and adult weight-treatment scope.
Open official sourceInjection-only MASH indication, F2 to F3 fibrosis, and accelerated approval context.
Open official sourceCurrent U.S. product, access, and administration information.
Open official sourceSource and label check completed August 1, 2026. Named clinical and operations review is still pending.
Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome, or PMOS, in 2026. Weight treatment should follow the medicine's approved indication while keeping metabolic health, menstrual history, contraception, pregnancy goals, emotional wellbeing, and specialist needs visible.
Wegovy is evaluated for chronic weight management, not as an FDA-approved treatment for PMOS or PCOS itself.
Connect the Wegovy evaluation with weight history, metabolic risks, current medicines, and reproductive plans.
Review the current pregnancy warning and the labeled preconception stopping interval.
GLP-1-based obesity medicines are not FDA approved to treat PMOS or PCOS itself. A clinician must confirm general weight-management eligibility, safety, the correct product, and current insurance or pharmacy requirements.
General information only. This information is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 2, 2026 from the sources cited here. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.
(917) 310-3371